RENMAB
Live / Registered — Registered (as of 18 Nov 2025)
What this means for you
Registered since 18 Nov 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88985441
- Registration number
- 8026774
- Mark type
- Stylized text
- Filed
- 31 Jul 2019
- Published for opposition
- 17 Aug 2021
- Registered
- 18 Nov 2025
- Attorney of record
- CYNTHIA JOHNSON WALDEN
Goods and services
- Class 001 — Chemicals: (Based on 44(e)) Chemical additives for insecticides; nitrogen fertilizer; food preservative chemicals; biological preparations not for medical or veterinary use; radioactive elements for scientific purposes; diagnostic preparations not for medical or veterinary use; protein in raw material form for scientific and medical research, and industrial use; plasticizers being industrial chemicals; industrial adhesives; industrial chemicals, not for medical use
- Class 031 — Natural agricultural products: (Based on 44(e)) Live experimental animal; live animals; live poultry; live hamster; live swine; living trees; plant seeds; hay; living plants
- Class 042 — Scientific and technological services: (Based on 44(e)) Drug development services for others provided via a platform for antibody discovery that features experimental animal research; drug evaluations being pharmaceutical research provided via a platform for antibody discovery that features experimental animal research; pharmaceutical research provided via a platform for antibody discovery that features experimental animal research; Implementation of early assessment in new drug development fields for others, involving experimental animals, to support the development by others of pharmaceutical preparations and medicines; development of pharmaceutical preparations and medicines provided via a platform for antibody discovery that features experimental animal research; clinical trials being pharmaceutical and scientific research services provided via a platform for antibody discovery that features experimental animal research; package design; research and development of antibodies provided via a platform for antibody discovery that features experimental animal research; research and development of new products for others provided via a platform for antibody discovery that features experimental animal research; products development for others provided via a platform for antibody discovery that features experimental animal research; consulting services in biotechnology development fields involving experimental animal research and antibodies discovered from the same, the aforementioned also provided via a platform for antibody discovery that features experimental animal research; biological research and analyses provided via a platform for antibody discovery that features experimental animal research; biochemistry research and analyses provided via a platform for antibody discovery that features experimental animal research; biotechnology research provided via a platform for antibody discovery that features experimental animal research
Owner
- BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., Daxing District, Beijing, CN
- BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., Daxing District, Beijing, CN
- BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., BEIJING, CN
- Beijing Biocytogen Co., Ltd., Beijing, CN
Prosecution history
- 18 Nov 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 18 Nov 2025 — REGISTERED-PRINCIPAL REGISTER
- 27 Oct 2025 — 1(B) BASIS DELETED; PROCEED TO REGISTRATION
- 27 Oct 2025 — NOTICE OF ALLOWANCE CANCELLED
- 27 Oct 2025 — DIVISIONAL PROCESSING COMPLETE
- 18 May 2025 — DIVISIONAL REQUEST RECEIVED
- 23 Oct 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 02 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Oct 2025 — SOU EXTENSION 1 GRANTED
- 18 May 2025 — SOU EXTENSION 1 FILED
- 01 Oct 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 19 May 2025 — SOU TEAS EXTENSION RECEIVED
- 18 May 2025 — TEAS REQUEST TO DIVIDE RECEIVED
- 13 May 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 01 May 2025 — TEAS POST PUBLICATION AMENDMENT RECEIVED